Analytical Data
-
基因名
LILRB4
- Application
-
别名
LILRB4；ILT3；LIR5；Leukocyte immunoglobulin-like receptor subfamily B member 4
-
种属
Human
-
表达系统
E. coli
-
标签
His tag N-Terminus
-
纯度
Greater than 90% as determined by SDS-PAGE.
-
蛋白编号
Q8NHJ6
-
表达区间
17-257aa
-
氨基酸序列
PRTH MQAGPLPKPT LWAEPGSVIS WGNSVTIWCQ GTLEAREYRL DKEESPAPWD RQNPLEPKNK ARFSIPSMTE DYAGRYRCYY RSPVGWSQPS DPLELVMTGA YSKPTLSALP SPLVTSGKSV TLLCQSRSPM DTFLLIKERA AHPLLHLRSE HGAQQHQAEF PMSPVTSVHG GTYRCFSSHG FSHYLLSHPS DPLELIVSGS LEDPRPSPTR SVSTAAGPED QPLMPTGSVP HSGLRRHWEV LIGVLVVSIL LLSLLLFLLL QHWRQGKHRT LAQRQADFQR PPGAAEPEPK DGGLQRRSSP AADVQGENFC AAVKNTQPED GVEMDTRQSP HDEDPQA
-
分子量
31 kDa
-
内毒素
< 1.0 EU per μg protein as determined by the LAL method.
-
性状
Freeze-dried powder
-
缓冲液
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
复溶方法
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- 个性化定制
-
稳定性测试
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
保存条件 & 期限
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
运输条件
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
LILRB4, or Leukocyte Immunoglobulin-Like Receptor B4, is a member of the LILR family, which play a crucial role in immune regulation. This receptor is predominantly expressed on myeloid cells and contributes to the modulation of immune responses, particularly in the context of cancer and autoimmune diseases. Research has shown that LILRB4 can inhibit T cell activation and promote immune tolerance, making it an attractive target for therapeutic interventions. Its interaction with major histocompatibility complex (MHC) molecules enables it to regulate the balance between immune activation and inhibition. Recent studies have highlighted the potential of LILRB4 as a biomarker for various malignancies and as a candidate for immunotherapy strategies aimed at enhancing antitumor immunity. By developing recombinant LILRB4 proteins, researchers aim to better understand its structure, function, and role in immune pathways, paving the way for novel therapeutic approaches in oncology and autoimmunity. This research is particularly relevant given the increasing interest in leveraging immune checkpoints in cancer treatment and the need for precise immunomodulatory agents to improve patient outcomes.
